Asia Business Outlook Team | Monday, 01 June 2026
Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI) have joined forces to accelerate the development of a vaccine for the Bundibugyo strain of Ebola, marking a major step in global efforts to strengthen outbreak preparedness.
The Moderna-CEPI partnership to develop a Bundibugyo Ebola vaccine comes at a time when health authorities are raising concerns over the spread of the virus in parts of Central Africa, highlighting the urgent need for targeted medical solutions and stronger global health preparedness.
The vaccine initiative focuses on Bundibugyo ebolavirus (BDBV), a less common but potentially deadly strain of Ebola for which there is currently no approved vaccine. While existing vaccines have proven effective against the Zaire strain of Ebola, scientists and health organizations have long warned about the lack of treatment options for other variants, making Ebola vaccine development a global priority.
Also Read: Revolution Drug Doubles Survival in Pancreatic Cancer Trial
As part of the collaboration, CEPI has committed funding of up to $50 million to support Moderna’s vaccine candidate through preclinical research and early-stage clinical trials. The financial support is expected to help speed up testing and production capabilities, ensuring quicker deployment if the vaccine is found to be safe and effective through clinical trials.
The partnership comes amid increasing concerns over recent Ebola cases reported in Central Africa, particularly in regions vulnerable to cross-border transmission. Public health agencies are closely monitoring the situation and working to contain the spread through surveillance, treatment, and outbreak preparedness measures.
CEPI, an international organization that funds vaccine development for epidemic threats, is also supporting other vaccine programs to improve readiness against the Bundibugyo strain. These include projects involving the University of Oxford, the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI), strengthening the global response to infectious disease outbreaks.
The World Health Organization (WHO) has also emphasized the need for testing experimental vaccines and treatments specifically for the Bundibugyo strain. According to health experts, no vaccine has yet been approved for this variant, making continued vaccine research especially important in preventing future outbreaks.
Moderna plans to use its mRNA technology platform for the vaccine, the same system that gained worldwide recognition during the COVID-19 pandemic. Experts believe mRNA platforms could help shorten vaccine development timelines, enabling faster responses to emerging public health emergencies.
The collaboration reflects a growing trend of partnerships between pharmaceutical companies and global organizations to address infectious disease threats. With outbreaks continuing to challenge healthcare systems worldwide, the initiative highlights the importance of epidemic preparedness and stronger international cooperation.
.jpg)
